



# Assessing and Diagnosing OUD

Christopher Suelzer, MD.  
Primary care provider





# Objectives

- Define Opioid Use Disorder
- Pain and Opioid Use Disorder
- State Law regarding documentation / treatment
- Assessing overdose risk
- Addressing the stigma of addiction





# What is the Definition of Opioid Use Disorder?

(also know as opioid “addiction”)

According to the American Society of Addiction Medicine’s definition:

*Addiction is a primary, chronic and relapsing brain disease characterized by an individual pathologically pursuing reward and/or relief by substance use and other behaviors*



# How do You Diagnose Opioid Use Disorder (OUD)?

## 2 or more criteria = OUD:

- Using larger amounts/longer than intended
- Much time spent using
- Activities given up in order to use
- Physical/psychological problems associated with use
- Social/interpersonal problems related to use
- Neglected major role in order to use
- Hazardous use
- Repeated attempts to quit/control use
- Withdrawal \*
- Tolerance \*
- Craving

\*Does not count if taken only as prescribed and constitutes the sole criteria

DSM 5, American Psychiatric Association



Physical dependence  
on opioids

≠

Opioid use disorder  
(opioid addiction)





# DIAGNOSIS OF OPIOID USE DISORDER

- patient on opioids who does not have opioid use disorder (patient on 30 hydrocodone a month who takes them prn without any negative consequences)
- patient who clearly has opioid use disorder ( patient who converted to heroin with multiple negative consequences as a result)
- patient on high dose prescription pain meds who denies any negative consequences as long as they get their medication



Is this pain or is this addiction?





Is this pain or is this addiction?

**WRONG QUESTION**






# Is this pain or is this addiction?

- Far more complex,
- Large proportion of patients with SUD have pain, much smaller proportion of chronic pain patients have SUD
- Rates of pain are even higher in those receiving SUD treatment (up to 75%)
- Pain in SUD more disabling (38% vs 19% without SUD)
- Reciprocal relationship between pain and addiction



# The Spectrum of Opioid Use Disorder



**Fig. 2.** A pictorial representation of the continuum of opioid dependence among LTOT patients.



# COMPLEX PERSISTENT DEPENDENCE

- More complex than simple dependence
- Patients unwilling to taper opioids despite medical or functional deterioration
- Classic OUD behaviors emerge as opioids are tapered
- Large percentage have ongoing mental health issues (anxiety, depression, personality disorder, PTSD)



# How do You Diagnose Complex Pain Disorder

## 2 or more criteria

- Using larger amounts/longer than intended to control the pain
- Much time spent avoiding pain
- Activities given up in order due to pain
- Physical/psychological problems associated with pain
- Social/interpersonal problems related to pain
- Neglected major role due to pain
- Hazardous use to control pain
- Repeated attempts to quit/control use
- Withdrawal \*
- Tolerance \*
- Craving



# Multidimensional Approach to Complex Dependent Patients

- Dependency treatment
- Comorbidity treatment (psychiatric / medical)
- Polypharmacy Reduction
- Chronic pain treatment (nonpharmacological)



# Legal requirements for prescribing buprenorphine

Senate Enrolled Act No. 141



# Indiana Public Law 213

- Does not apply in
  - Correctional facility
  - Hospital
  - facility that is certified under IC 16-21-2
  - an opioid treatment program that has been certified or licensed by the division under IC-23-18
  - state institution
  - health facility licensed under IC 16-28
  - Indiana Veterans Home



# Indiana Public Law 213

- Requirements for prescribing:
  - Determine patients age
  - Initial assessment and a physical exam as appropriate for the patients condition and the health care providers scope of practice and obtain a medical history of the patient before treatment begins
  - Obtain substance use history and any substance use disorder diagnosis of the patient
  - Perform a mental health assessment
  - Obtain informed consent for treatment and establish the patient meets the requirements set forth in subsection d



# Indiana Public Law 213

- Require office visits of the patient in person throughout treatment
- Evaluate the patient's progress and document the patients progress with the treatment plan
- Perform toxicology screening (stimulants, alcohol, opioids including oxycodone, methadone and buprenorphine, THC, BNZ, Cocaine)
- Review INSPECT before induction and at least 4 times per year
- If female and child bearing potential perform pregnancy test at onset of treatment , counsel patient about risks , provide or refer for prenatal care



# Indiana Public Law 213

- Prescribe an overdose intervention drug and education
- Provide from an ongoing component of psychosocial supportive therapy with direction from the health care provider on the amount of therapy



# Indiana Public Law 213

- During office visits
  - evaluate and document patients progress and compliance
  - whether patient is meeting treatment goals
  - discussion of risks and benefits of ongoing buprenorphine treatment
- If toxicology testing shows an absence of the prescribed drug the provider must discuss and implement a plan to optimize medication adherence and schedule an earlier follow up with the patient
- If toxicology screening shows a presence of an illegal or nonprescribed drug the provider shall assess the risk of the patient to be successfully treatment



# Lethal doses comparison





# EDUCATE CLIENTS ON OVERDOSE RISK

**I'm on 205mg of methadone a day, and i've taken up to 700mg+ combined with clonazepam and clonidine and still wished I could have gotten higher. I'm tolerant to clonazepam also but not nearly as much so, 0.5mg a day will hold me in terms of physical symptoms, but i'm prescribed 1.5mg a day. I can take 5mg with 400mg-600mg methadone with no problems at all, even topping it off with a small dose of clonidine (0.15mgs or under that) if I can't nodd as much as I'd like to. Honestly when I started MMT I could have died several times over from a single 200mg dose."**



# Predictors of overdose

- **Concurrent use of benzo (1.6)**
- **Concurrent use of antipsychotics (2.3)**
- **Chronic lung disease (1.7)**
- **Dose of opioids taken (4.0)**
- **Alcohol use (1.9)**
- **Mood disorders (1.8)**
- **History of heart disease (5.3)**
- **Prior overdose history (28.5)**





**BOTTOM LINE**

**OPIOID USE DISORDER IS  
A  
FATAL DISEASE**





# EDUCATE CLIENTS ON OVERDOSE RISK

- **Ask them if they have or know someone who has overdosed, stories are more powerful than statistics**
- **Empathy, don't judge, build the relationship and trust**
- **Discuss the risks**
- **Offer Naloxone at the first visit (it may be your only chance)**



# Reducing Stigma

- Individuals with substance use disorders (SUDs) are highly stigmatized
- Although addiction is a brain disease, people with SUDs are often regarded as simply needing more willpower, rather than treatment
- Language use perpetuates stigma in healthcare and in society at large
- Stigma prevents people from seeking care
- **What are some situations in which you see stigmatizing behavior or language related to SUDs?**
- Health care teams can send a powerful message by avoiding stigmatizing language and behavior



# References

American Society of Addiction Medicine. (2011). Public Policy Statement: Definition of Addiction. Chevy Chase, MD: American Society of Addiction Medicine. Available at [http://www.asam.org/docs/publicpolicy-statements/1definition\\_of\\_addiction\\_long\\_4-11.pdf?sfvrsn=2](http://www.asam.org/docs/publicpolicy-statements/1definition_of_addiction_long_4-11.pdf?sfvrsn=2)

Botticelli MA, Koh HK. Changing the language of addiction. JAMA October 4, 2016;316(13):1361

Broyles LM, Binswanger IA, Jenkins JA, et al. [Confronting inadvertent stigma and pejorative language in addiction scholarship: a recognition and response.](#) Subst Abus. 2014;35(3):217-21

[Campbell G](#)<sup>1</sup>, [Nielsen S](#)<sup>1</sup>, [Larance B](#)<sup>1</sup>, et al. Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. [Pain Med.](#) 2015 Sep;16(9):1745-58. doi: 10.1111/pme.12773. Epub 2015 May 22.

CDC Guidelines for prescribing opioids for chronic pain: United States 2016. <https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm>



CDC Opioid Overdose Information

<https://www.cdc.gov/drugoverdose/epidemic/>

[Compton WM](#), [Jones CM](#), [Baldwin GT](#) Relationship between Nonmedical Prescription-Opioid Use and Heroin Use. [N Engl J Med](#). 2016 Jan 14;374(2):154-63. doi: 10.1056/NEJMra1508490.

[Dart RC](#)<sup>1</sup>, [Surratt HL](#), [Cicero TJ](#), et al. Trends in opioid analgesic abuse and mortality in the United States. [N Engl J Med](#). 2015 Jan 15;372(3):241-8. doi: 10.1056/NEJMsa1406143.

[Degenhardt L](#)<sup>1</sup>, [Bruno R](#)<sup>2</sup>, [Lintzeris N](#)<sup>3</sup>, et al. Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): a cohort study. [Lancet Psychiatry](#). 2015 Apr;2(4):314-22. doi: 10.1016/S2215-0366(15)00005-X. Epub 2015 Mar 31.

Megan Crowley-Matoka, Somnath Saha, Steven K. Dobscha et al. [Problems of Quality and Equity in Pain Management: Exploring the Role of Biomedical Culture \(pages 1312–1324\)](#) [Pain Medicine](#): 6 OCT 2009 | DOI: 10.1111/j.1526-4637.2009.00716.

Staton LJ, Panda M, Chen I, *et al*. When race matters: Disagreement in pain perception between patients and their physicians in primary care. [J Natl Med Assoc](#) 2007;99(5):532–8

US Department of Health and Human Services (HHS) Office of the Surgeon General, Facing Addiction in America: the Surgeon General's Report on Alcohol, Drugs, and Health. Washington, DC, HHS, November 2016.